Malignant Transformation of Fanconi Anemia Complementation Group D2-deficient (
Cell Line, Tumor
Cell Transformation, Neoplastic
/ genetics
Fanconi Anemia Complementation Group D2 Protein
/ genetics
Hematopoietic Stem Cells
/ metabolism
Human papillomavirus 16
/ genetics
Humans
Interleukin-3
/ genetics
Oncogene Proteins, Viral
/ genetics
Oncogenes
/ genetics
Papillomavirus E7 Proteins
/ genetics
Plasmids
/ genetics
Repressor Proteins
/ genetics
Transfection
/ methods
E6 and E7 oncogene
Fanconi anemia
Human Papillomavirus
Journal
In vivo (Athens, Greece)
ISSN: 1791-7549
Titre abrégé: In Vivo
Pays: Greece
ID NLM: 8806809
Informations de publication
Date de publication:
Historique:
received:
10
12
2018
revised:
29
12
2018
accepted:
11
01
2019
entrez:
27
2
2019
pubmed:
26
2
2019
medline:
6
6
2019
Statut:
ppublish
Résumé
To demonstrate that Fanconi anemia complementation group D2-deficient (Fancd2 In order to determine whether a single HPV type 16 (HPV16) oncogene induced malignant transformation, Fancd2 Fancd2 A single HPV16 oncogene is adequate to produce malignant transformation of Fancd2
Identifiants
pubmed: 30804107
pii: 33/2/303
doi: 10.21873/invivo.11476
pmc: PMC6506306
doi:
Substances chimiques
E6 protein, Human papillomavirus type 16
0
FANCD2 protein, human
0
Fanconi Anemia Complementation Group D2 Protein
0
IL3 protein, human
0
Interleukin-3
0
Oncogene Proteins, Viral
0
Papillomavirus E7 Proteins
0
Repressor Proteins
0
oncogene protein E7, Human papillomavirus type 16
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
303-311Subventions
Organisme : NIAID NIH HHS
ID : U19 AI068021
Pays : United States
Informations de copyright
Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
Références
Oncogene. 1999 Apr 8;18(14):2381-6
pubmed: 10327059
Mol Cell. 2001 Feb;7(2):249-62
pubmed: 11239454
Oncogene. 2002 Jan 10;21(2):165-75
pubmed: 11803460
Arch Otolaryngol Head Neck Surg. 2003 Jan;129(1):106-12
pubmed: 12525204
Arch Virol. 2004 Dec;149(12):2379-92
pubmed: 15290353
Blood. 2005 Jan 1;105(1):67-73
pubmed: 15331448
Int J Biochem Cell Biol. 2007;39(11):2006-11
pubmed: 17768080
Cancer Res. 2008 Apr 15;68(8):2622-31
pubmed: 18413729
Oncogene. 2009 Feb 5;28(5):674-85
pubmed: 19015634
Nat Rev Cancer. 2010 Aug;10(8):550-60
pubmed: 20592731
Cancer Res. 2010 Dec 1;70(23):9959-68
pubmed: 20935219
Hematology Am Soc Hematol Educ Program. 2011;2011:492-7
pubmed: 22160080
Nucleic Acids Res. 2012 Sep 1;40(17):8425-39
pubmed: 22753026
Head Neck. 2013 Oct;35(10):E292-8
pubmed: 22965917
Int J Oncol. 2013 Aug;43(2):383-93
pubmed: 23708675
Cancer Res. 2013 Aug 1;73(15):4791-800
pubmed: 23749640
Oncogene. 2014 Jun 26;33(26):3383-91
pubmed: 24013229
Radiat Res. 2014 Jan;181(1):76-89
pubmed: 24397476
Radiat Res. 2014 Jul;182(1):35-49
pubmed: 24932534
J Virol. 2014 Oct;88(19):11315-26
pubmed: 25031356
Oral Surg Oral Med Oral Pathol Oral Radiol. 2014 Sep;118(3):e74-8
pubmed: 25151594
Immun Inflamm Dis. 2014 Aug;2(2):63-75
pubmed: 25400927
J Mol Biol. 2014 Dec 12;426(24):4030-4048
pubmed: 25451029
Rev Med Virol. 2015 Nov;25(6):345-53
pubmed: 25776992
Ecancermedicalscience. 2015 Apr 29;9:526
pubmed: 25987895
J Virol. 2015 Dec 23;90(5):2639-52
pubmed: 26699641
Radiat Res. 2016 Feb;185(2):134-50
pubmed: 26789701
Cell Stem Cell. 2016 May 5;18(5):668-81
pubmed: 27053300
Oncotarget. 2016 Oct 18;7(42):68449-68472
pubmed: 27637088
Radiat Res. 2018 Jun;189(6):560-578
pubmed: 29584588
EMBO J. 1994 Mar 1;13(5):1084-92
pubmed: 8131742
Virology. 1994 Jan;198(1):169-74
pubmed: 8259651
J Virol. 1996 Mar;70(3):1873-81
pubmed: 8627712
Virology. 1997 Jan 6;227(1):255-9
pubmed: 9007083
Proc Natl Acad Sci U S A. 1998 Mar 3;95(5):2290-5
pubmed: 9482878
Mol Carcinog. 1998 Mar;21(3):215-22
pubmed: 9537653
Virology. 1998 Apr 25;244(1):97-107
pubmed: 9581783